Author Archives: Steve Bryson PhD

Combinations of immune proteins drive different SLE symptoms

Different combinations and elevated levels of antiviral immune signaling proteins, called interferons (IFNs), were associated with differences in the symptoms and severity of systemic lupus erythematosus (SLE), a study shows. While IFNs are known to play a role in the disease, increases in IFN levels don ‘t explain many…

1st lupus patient treated with off-the-shelf FT819 CAR T-cell therapy

A 27-year-old woman with hard-to-treat systemic lupus erythematosus (SLE), the most common type of lupus, became the first patient treated in an early clinical trial evaluating FT819, Fate Therapeutics’ off-the-shelf CAR T-cell therapy candidate. The Phase 1 study (NCT06308978), taking place at the University of Minnesota Medical…

Modified immune Tregs show promise in treating lupus nephritis

Modified anti-inflammatory T-regulatory immune cells, known as Tregs, were able to suppress autoimmune activity in cells and in a mouse model of lupus nephritis, a common complication of lupus marked by kidney inflammation, a new study reports. These findings support the development of a Treg-based treatment that uses a…

Clinical testing of cell-based NKX019 in lupus nephritis to begin

The U.S. Food and Drug Administration (FDA) has approved Nkarta’s request to launch a clinical trial in the U.S. to test its experimental therapy NKX019 in people with lupus nephritis, a lupus complication marked by kidney inflammation and damage. The multi-center, dose-escalation study will assess the safety and clinical…

No safety concerns seen one month after dosing with KYV-101 for lupus

No signs of neurotoxicity were seen for 28 days after the first patient in a Phase 1 clinical trial was dosed with KYV-101, Kyverna Therapeutics’ investigational cell therapy for lupus nephritis, a lupus complication marked by kidney damage. A standard 4-week post-infusion observation period in such clinical trials is…

Kyverna, Verily team up to identify KYV-101 response biomarkers

Kyverna Therapeutics will use Verily Life Sciences’ high-resolution Immune Profiler to identify biomarkers to measure responses to KYV-101, Kyverna’s experimental cell therapy for lupus-related kidney disease. KYV-101 is being evaluated in an open-label trial, which is recruiting nine to 12 patients at clinical sites across the U.S.